US26818M1080
© Globe Newswire
11.12.2025
DYN
LISTED
NASDAQ
Dyne Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares
News Preview
WALTHAM, Mass., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced the closing of its previously announced upsized underwritten public offering of 21,827,549 shares of its co...
Themefolio
Profiler
Peergroup
© Globe Newswire
10.12.2025
DYN
LISTED
NASDAQ
Dyne Therapeutics Announces Pricing of Upsized $350.0 Million Public Offering of Common Stock
News Preview
WALTHAM, Mass., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced the pricing of an upsized underwritten public offering of 18,980,478 shares of its common stock at a public...
Themefolio
Profiler
Peergroup
© Globe Newswire
08.12.2025
DYN
LISTED
NASDAQ
Dyne Therapeutics Announces Proposed Public Offering of Common Stock
News Preview
WALTHAM, Mass., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced that it has commenced an underwritten public offering of $300,000,000 of shares of its common stock. Dyne a...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Leerverkaufsstatistiken, Hedge-Fund Aktivitäten und viele weitere nutzerwertige Informationen benutzerfreundlich aufbereitet
© Globe Newswire
08.12.2025
DYN
LISTED
NASDAQ
Dyne Therapeutics Announces Positive Topline Results from Phase 1/2 DELIVER Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy (DMD)
News Preview
- Registrational Expansion Cohort (REC) met primary endpoint, demonstrating statistically significant increase in dystrophin to 5.46% at 6 months (muscle content-adjusted; p<0.0001), replicating the same 7-fold change from baseline previously observed at the registrational dose -...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© Globe Newswire
07.12.2025
DYN
LISTED
NASDAQ
Dyne Therapeutics to Host Investor Conference Call and Webcast to Review Topline Results from Registrational Expansion Cohort (REC) of DELIVER Clinical Trial of Z-Rostudirsen (DYNE-251) in Duchenne Muscular Dystrophy; Tomorrow, December 8 at 8:00 a.m. ET
News Preview
WALTHAM, Mass., Dec. 07, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced that it plans to announce topline clinical results from the Registrational Expansion Cohort (REC) of the Ph...
Themefolio
Profiler
Peergroup
© Globe Newswire
05.11.2025
DYN
LISTED
NASDAQ
Dyne Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights
News Preview
- Topline data from Registrational Expansion Cohort of DELIVER trial of zeleciment rostudirsen (z-rostudirsen, also known as DYNE-251) in DMD on track for December 2025 to support potential submission for U.S. Accelerated Approval in Q2 2026 -...
Themefolio
Profiler
Peergroup
© Globe Newswire
03.11.2025
DYN
LISTED
NASDAQ
Dyne Therapeutics to Present at Upcoming Investor Conferences
News Preview
WALTHAM, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced that management is scheduled to present at the following upcoming investor conferences:...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.10.2025
DYN
LISTED
NASDAQ
Dyne Therapeutics Announces Additional One-Year Clinical Data Demonstrating Functional Improvement from Phase 1/2 ACHIEVE Trial of Zeleciment Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1)
News Preview
- Robust improvement demonstrated across diverse set of clinical measures -...
Themefolio
Profiler
Peergroup
© Globe Newswire
02.10.2025
DYN
LISTED
NASDAQ
Dyne Therapeutics Appoints Brian Posner to its Board of Directors
News Preview
WALTHAM, Mass., Oct. 02, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced the appointment of Brian Posner to its Board of Directors. Mr. Posner brings 35 years of executive, investm...
Themefolio
Profiler
Peergroup
© Globe Newswire
29.09.2025
DYN
LISTED
NASDAQ
Dyne Therapeutics Receives Orphan Drug Designation in Japan for DYNE-251 in Duchenne Muscular Dystrophy
News Preview
- Data from ongoing DELIVER trial demonstrated sustained functional improvement through 18 months; results from Registrational Expansion Cohort expected late 2025 -...
Themefolio
Profiler
Peergroup
© Globe Newswire
27.08.2025
DYN
LISTED
NASDAQ
Dyne Therapeutics to Present at Upcoming Investor Conferences
News Preview
WALTHAM, Mass., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced that management is scheduled to present at the following upcoming investor conferences:...
Themefolio
Profiler
Peergroup
© Globe Newswire
04.08.2025
DYN
LISTED
NASDAQ
Dyne Therapeutics Announces FDA Breakthrough Therapy Designation for DYNE-251 in Duchenne Muscular Dystrophy (DMD)
News Preview
- Data from the DELIVER registrational expansion cohort is expected in late 2025, with a potential BLA submission for U.S. accelerated approval anticipated in early 2026 - ...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© Globe Newswire
28.07.2025
DYN
LISTED
NASDAQ
Dyne Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights
News Preview
- Expected cash runway extended into Q3 2027, beyond multiple potential inflection points including Dyne’s first planned commercial launch in early 2027 -...
Themefolio
Profiler
Peergroup
© Globe Newswire
01.07.2025
DYN
LISTED
NASDAQ
Dyne Therapeutics Announces Pricing of $200.0 Million Public Offering of Common Stock
News Preview
WALTHAM, Mass., June 30, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced the pricing of an underwritten public offering of 24,242,425 shares of its common stock at a public offerin...
Themefolio
Profiler
Peergroup
© Globe Newswire
30.06.2025
DYN
LISTED
NASDAQ
Dyne Therapeutics Announces Proposed Public Offering of Common Stock
News Preview
WALTHAM, Mass., June 30, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced that it has commenced an underwritten public offering of $200,000,000 of shares of its common stock. Dyne a...
Themefolio
Profiler
Peergroup
© BusinessWire
17.06.2025
DYN
LISTED
NASDAQ
Dyne Therapeutics Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – DYN
News Preview
The DJS Law Group announces that it is investigating claims on behalf of investors of Dyne Therapeutics (“Dyne” or “the Company”) (NASDAQ: DYN) for violations of the securities laws.
INVESTIGATION DETAILS: The investigation focuses on whether the Company issued misleading statements and/or failed to disclose information pertinent to investors. D...
Themefolio
Profiler
Peergroup
© Globe Newswire
16.06.2025
DYN
LISTED
NASDAQ
Dyne Therapeutics to Host Investor Conference Call and Webcast to Provide Update on DYNE-101 for Myotonic Dystrophy Type 1, Tomorrow Tuesday, June 17 at 8:00 a.m. ET
News Preview
WALTHAM, Mass., June 16, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage neuromuscular disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced it plans to provide an update on DYNE-101 in myotonic dystrophy type 1 (DM1) tomo...
Themefolio
Profiler
Peergroup
© Globe Newswire
20.03.2025
DYN
LISTED
NASDAQ
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Financial Officer
News Preview
WALTHAM, Mass., March 20, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases, today announced it has granted inducement equity awards to its newly appointed Chief Financial Officer, Erick J. Lu...
Themefolio
Profiler
Peergroup
© Globe Newswire
20.03.2025
DYN
LISTED
NASDAQ
Dyne Therapeutics Announces Appointment of Erick J. Lucera as Chief Financial Officer
News Preview
- Proven financial leader brings decades of experience in capital allocation, business development and shareholder value creation -...
Themefolio
Profiler
Peergroup
© Globe Newswire
16.03.2025
DYN
LISTED
NASDAQ
Dyne Therapeutics Announces New Long-Term Clinical Data from Phase 1/2 DELIVER Trial of DYNE-251 in Duchenne Muscular Dystrophy Demonstrating Unprecedented and Sustained Functional Improvement Through 18 Months
News Preview
- Continued favorable safety profile for DYNE-251 -...
Themefolio
Profiler
Peergroup
© Globe Newswire
27.02.2025
DYN
LISTED
NASDAQ
Dyne Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights
News Preview
- Received FDA Fast Track Designation for DYNE-101 in DM1 -...
Themefolio
Profiler
Peergroup
© Globe Newswire
14.02.2025
DYN
LISTED
NASDAQ
Dyne Therapeutics Announces Upcoming Presentations at the 2025 MDA Clinical & Scientific Conference
News Preview
- Data from DELIVER and ACHIEVE Clinicals Trial to be Presented -...
Themefolio
Profiler
Peergroup
© BusinessWire
16.09.2024
DYN
LISTED
NASDAQ
DYN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Dyne Therapeutics, Inc. and Encourages Investors to Contact the Firm!
News Preview
Attorney Advertising-- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Dyne Therapeutics, Inc. (“Dyne” or “the Company”) (NASDAQ: DYN). Investors who purchased Dyne securities are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: bgandg.com/DYN....
Themefolio
Profiler
Peergroup
© BusinessWire
10.09.2024
DYN
LISTED
NASDAQ
Kirby McInerney LLP Announces Investigation of Shareholder Claims Against Dyne Therapeutics, Inc. (DYN)
News Preview
The law firm of Kirby McInerney LLP is investigating potential claims against Dyne Therapeutics, Inc. (“Dyne” or the “Company”) (NASDAQ: DYN). The investigation concerns whether Dyne and/or certain of its officers have violated the federal securities laws and/or engaged in other unlawful business practices.
[Click here to learn more about the inv...
Themefolio
Profiler
Peergroup
© BusinessWire
08.09.2024
DYN
LISTED
NASDAQ
DYN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Dyne Therapeutics, Inc. and Encourages Investors to Contact the Firm!
News Preview
Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Dyne Therapeutics, Inc. (“Dyne” or “the Company”) (NASDAQ: DYN). Investors who purchased Dyne securities are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: bgandg.com/DYN....
Themefolio
Profiler
Peergroup
© BusinessWire
04.09.2024
DYN
LISTED
NASDAQ
DYN Investors Have Opportunity to Join Dyne Therapeutics, Inc. Fraud Investigation with the Schall Law Firm
News Preview
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Dyne Therapeutics, Inc. (“Dyne” or “the Company”) (NASDAQ: DYN) for violations of the securities laws.
The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to...
Themefolio
Profiler
Peergroup
© Globe Newswire
12.08.2024
DYN
LISTED
NASDAQ
Dyne Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights
News Preview
- Recent Data from ACHIEVE Trial of DYNE-101 in DM1 and DELIVER Trial of DYNE-251 in DMD Demonstrated Compelling Impact on Key Disease Biomarkers and Improvement in Multiple Functional Endpoints -...
Themefolio
Profiler
Peergroup
© Globe Newswire
13.06.2024
DYN
LISTED
NASDAQ
Dyne Therapeutics Presents New Preclinical Data for its Facioscapulohumeral Muscular Dystrophy Program During the FSHD Society International Research Congress
News Preview
- Leveraging the FORCE™ Platform, DYNE-302 Achieved Robust and Durable DUX4 Suppression and Functional Benefit in FSHD Preclinical Models -...
Themefolio
Profiler
Peergroup
© Globe Newswire
22.05.2024
DYN
LISTED
NASDAQ
Dyne Therapeutics Announces Pricing of $325.5 Million Public Offering of Common Stock
News Preview
WALTHAM, Mass., May 21, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced the pricing of an underwritten public offering of 10,500,000 shares of its common stock a...
Themefolio
Profiler
Peergroup
© Globe Newswire
19.05.2024
DYN
LISTED
NASDAQ
Dyne Therapeutics to Host Virtual Investor Event to Review New Clinical Data from the ACHIEVE and DELIVER Trials Tomorrow, May 20 at 8:00 a.m. ET
News Preview
WALTHAM, Mass., May 19, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced it now plans to report new efficacy and safety data from its Phase 1/2 ACHIEVE and DELIV...
Themefolio
Profiler
Peergroup
© Globe Newswire
02.05.2024
DYN
LISTED
NASDAQ
Dyne Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
News Preview
- Additional Clinical Data from ACHIEVE Trial of DYNE-101 in DM1 and DELIVER Trial of DYNE-251 in DMD Anticipated in the Second Half of 2024 -...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
